INR 142.78
(-0.61%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 109.75 Million INR | -21.61% |
2022 | 1.45 Billion INR | 5.83% |
2021 | 1.37 Billion INR | 42.71% |
2020 | 966.43 Million INR | -27.76% |
2019 | 1.33 Billion INR | -42.69% |
2018 | 2.33 Billion INR | 20.64% |
2017 | 1.93 Billion INR | -4.55% |
2016 | 2.02 Billion INR | 15.86% |
2015 | 1.74 Billion INR | 36.84% |
2014 | 1.27 Billion INR | 16.58% |
2013 | 1.09 Billion INR | 20.74% |
2012 | 908.4 Million INR | 9.88% |
2011 | 826.7 Million INR | 28.28% |
2010 | 644.46 Million INR | 4.85% |
2009 | 614.62 Million INR | 11.68% |
2008 | 550.35 Million INR | 7.67% |
2007 | 511.14 Million INR | 11.59% |
2006 | 458.06 Million INR | 11.68% |
2005 | 410.16 Million INR | 30.8% |
2004 | 313.58 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 562.36 Million INR | -89.67% |
2024 Q1 | 249.18 Million INR | -9.46% |
2023 Q2 | 282.96 Million INR | -15.47% |
2023 Q4 | 275.21 Million INR | -45.23% |
2023 Q3 | 502.45 Million INR | 77.57% |
2023 Q1 | 334.76 Million INR | -6.5% |
2023 FY | 1.14 Billion INR | -21.61% |
2022 Q3 | 562.58 Million INR | 103.07% |
2022 Q1 | 261.99 Million INR | 7.66% |
2022 FY | 1.45 Billion INR | 5.83% |
2022 Q2 | 277.04 Million INR | 5.75% |
2022 Q4 | 358.04 Million INR | -36.36% |
2021 Q3 | 381.34 Million INR | 27.82% |
2021 Q4 | 243.36 Million INR | -36.18% |
2021 FY | 1.37 Billion INR | 42.71% |
2021 Q1 | 456.16 Million INR | 97.95% |
2021 Q2 | 298.35 Million INR | -34.6% |
2020 Q3 | 292.61 Million INR | 5.84% |
2020 Q2 | 276.47 Million INR | 65.65% |
2020 Q1 | 166.9 Million INR | -51.3% |
2020 FY | 966.43 Million INR | -27.76% |
2020 Q4 | 230.44 Million INR | -21.25% |
2019 Q3 | 312.97 Million INR | -47.2% |
2019 Q2 | 592.72 Million INR | -24.4% |
2019 FY | 1.33 Billion INR | -42.69% |
2019 Q1 | 784.04 Million INR | -15.27% |
2019 Q4 | 342.69 Million INR | 9.5% |
2018 Q2 | 541.04 Million INR | -15.92% |
2018 FY | 2.33 Billion INR | 20.64% |
2018 Q4 | 925.37 Million INR | 304.83% |
2018 Q3 | 228.58 Million INR | -57.75% |
2018 Q1 | 643.48 Million INR | 0.0% |
2017 FY | 1.93 Billion INR | -4.55% |
2016 Q4 | 491.5 Million INR | 0.0% |
2016 FY | 2.02 Billion INR | 15.86% |
2015 FY | 1.74 Billion INR | 36.84% |
2015 Q2 | 503.46 Million INR | 69.51% |
2015 Q3 | 327.55 Million INR | -34.94% |
2015 Q1 | 297.02 Million INR | -40.16% |
2015 Q4 | 383.65 Million INR | 17.13% |
2014 FY | 1.27 Billion INR | 16.58% |
2014 Q1 | 240.88 Million INR | -17.18% |
2014 Q4 | 496.36 Million INR | 73.37% |
2014 Q3 | 286.3 Million INR | 12.22% |
2014 Q2 | 255.13 Million INR | 5.91% |
2013 Q2 | 344.93 Million INR | 12.41% |
2013 Q1 | 306.84 Million INR | 26.06% |
2013 Q3 | 270.13 Million INR | -21.69% |
2013 Q4 | 290.85 Million INR | 7.67% |
2013 FY | 1.09 Billion INR | 20.74% |
2012 Q2 | 213.5 Million INR | -6.14% |
2012 Q3 | 224 Million INR | 4.92% |
2012 Q4 | 243.42 Million INR | 8.67% |
2012 FY | 908.4 Million INR | 9.88% |
2012 Q1 | 227.48 Million INR | 0.0% |
2011 FY | 826.7 Million INR | 28.28% |
2010 FY | 644.46 Million INR | 4.85% |
2009 FY | 614.62 Million INR | 11.68% |
2008 FY | 550.35 Million INR | 7.67% |
2007 FY | 511.14 Million INR | 11.59% |
2006 FY | 458.06 Million INR | 11.68% |
2005 FY | 410.16 Million INR | 30.8% |
2004 FY | 313.58 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sigachi Industries Limited | 579.88 Million INR | 81.074% |
Ind-Swift Limited | 946.56 Million INR | 88.405% |
Bajaj HealthCare Limited | 985.34 Million INR | 88.862% |
Sakar Healthcare Limited | 204.07 Million INR | 46.222% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.803% |
Innova Captab Limited | 931.03 Million INR | 88.212% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.225% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 95.563% |
Morepen Laboratories Limited | 1.98 Billion INR | 94.478% |
Mankind Pharma Limited | 29.27 Billion INR | 99.625% |
Sequent Scientific Limited | 2.9 Billion INR | 96.218% |
Wanbury Limited | 978.96 Million INR | 88.789% |
Laurus Labs Limited | 11.9 Billion INR | 99.078% |
Nectar Lifesciences Limited | 932.7 Million INR | 88.233% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.057% |
Alembic Limited | 872.45 Million INR | 87.421% |
Hikal Limited | 4.46 Billion INR | 97.541% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.308% |
Neuland Laboratories Limited | 2.92 Billion INR | 96.254% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 99.258% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.766% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 95.014% |
Themis Medicare Limited | 1.12 Billion INR | 90.251% |
RPG Life Sciences Limited | 1.63 Billion INR | 93.29% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.912% |
Lupin Limited | 125.09 Billion INR | 99.912% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 94.759% |
Wockhardt Limited | 8.48 Billion INR | 98.706% |
Vaishali Pharma Limited | 84.02 Million INR | -30.61% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 96.43% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 74.974% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.241% |
FDC Limited | 3.49 Billion INR | 96.864% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.886% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 73.389% |
Eris Lifesciences Limited | 4.94 Billion INR | 97.78% |
Venus Remedies Limited | 1.91 Billion INR | 94.273% |
ZIM Laboratories Limited | 1.01 Billion INR | 89.166% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 92.267% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -88.289% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 94.953% |
Shilpa Medicare Limited | 3.33 Billion INR | 96.708% |
Albert David Limited | 1.02 Billion INR | 89.305% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.64% |
Hester Biosciences Limited | 908.84 Million INR | 87.924% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 92.176% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 95.703% |
Gufic Biosciences Limited | 1.18 Billion INR | 90.751% |
Windlas Biotech Limited | 1 Billion INR | 89.096% |
Procter & Gamble Health Limited | 2.99 Billion INR | 96.336% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -672.18% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | 32.348% |
Granules India Limited | 10.31 Billion INR | 98.936% |
Aarti Drugs Limited | 1.16 Billion INR | 90.599% |
Bal Pharma Limited | 555.62 Million INR | 80.248% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.666% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.929% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 89.783% |
Medicamen Biotech Limited | 335.16 Million INR | 67.255% |
Unichem Laboratories Limited | 6.72 Billion INR | 98.368% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 75.91% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -1509.238% |
Valiant Laboratories Limited | 138.02 Million INR | 20.488% |
Orchid Pharma Limited | 800.77 Million INR | 86.294% |
Medico Remedies Limited | 59.67 Million INR | -83.913% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 94.833% |
Ipca Laboratories Limited | 18.98 Billion INR | 99.422% |
Brooks Laboratories Limited | 51.18 Million INR | -114.439% |
Syncom Formulations (India) Limited | 345.63 Million INR | 68.247% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.828% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.488% |
NATCO Pharma Limited | 10.05 Billion INR | 98.909% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -137.781% |
Strides Pharma Science Limited | 9.16 Billion INR | 98.802% |
Indoco Remedies Limited | 12.06 Billion INR | 99.09% |
Alpa Laboratories Limited | 127.38 Million INR | 13.84% |
Lasa Supergenerics Limited | 291.17 Million INR | 62.308% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 96.433% |